Endurant Capital Management LP Incyte Corp Transaction History

Endurant Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $2.07 Million - $2.6 Million	31,211 New	31,211 $2.37 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $1.18 Million - $1.63 Million	-19,420 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $996,720 - $1.21 Million	12,000 Added 161.73%	19,420 $1.62 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $1.33 Million - $1.65 Million	-14,180 Reduced 65.65%	7,420 $703,000
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $2.36 Million - $2.99 Million	21,600	21,600 $2.52 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.